Jeff Hansen
| This email address is being protected from spambots. You need JavaScript enabled to view it.Research Editor
jeffhans@uab.edu | (205) 209-2355Communicates UAB research discoveries and initiatives from across the university for a variety of audiences.
Specific beats:
- Alabama Drug Discovery Alliance
- Biochemistry and Molecular Genetics
- Biomatrix Engineering and Regenerative Medicine
- Cell biology
- Center for Biophysical Sciences and Engineering
- CCTS
- Center for Metabolic Bone Disease
- Microbiology
- Neurobiology
- Comprehensive Neuroscience Center
- Pathology, research shared with MS2
- Pharmacology and Toxicology
- Physiology and Biophysics
- UAB Research Foundation/IIE
- Research Administration
Fecal-dominant donor microbes in the recipient patients after fecal microbe transplantation did not correlate with response to anti-PD-1 therapy.
Yabing Chen, Ph.D., is the first researcher at the Birmingham VA to receive this highest honor for a non-physician scientist.
The higher infectivity correlates with mutations that increase viral binding to a cell surface glucosaminoglycan, heparan sulfate.
This finding upends the long-held paradigm that priming during lung infections takes place only in the draining lymph nodes, and it will be key to developing more efficient vaccinations and therapies for respiratory challenges.
A Bcl-2 inhibitor that has FDA approval for treatment of several leukemias reversed lung fibrosis in a bleomycin mouse model.
In this arteriolar niche, breast cancer stem cells and arteriolar endothelial cells cross-talk using a well-known signaling pathway. Targeting this pathway may offer therapeutic potential.
Understanding how reductive stress is controlled may help personalize treatment of heart failure patients, leading to better outcomes.